Baxter International (BAX) Cost of Revenue (2009 - 2026)

Baxter International (BAX) has 18 years of Cost of Revenue data on file, last reported at $1.8 billion in Q1 2026.

• Cost of Revenue for Q1 2026 came in at $1.8 billion, up 2.61% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.0 billion (up 2.13% YoY), and the FY2025 annual result was $7.9 billion, up 18.24% from the prior year.
• Cost of Revenue advanced to $1.8 billion in Q1 2026 per BAX's latest filing, from $1.8 billion in the prior quarter.
• Over five years, Cost of Revenue peaked at $2.6 billion in Q2 2023 and troughed at -$1.2 billion in Q4 2023.
• A 5-year average of $1.7 billion and a median of $2.0 billion in 2024 frame the typical range for Cost of Revenue.
• The sharpest annual moves came in 2022 and 2024: Cost of Revenue tumbled 131.0% in 2022, then soared 247.65% in 2024.
• A 5-year view of Cost of Revenue shows it stood at -$575.0 million in 2022, then sank by 111.3% to -$1.2 billion in 2023, then soared by 247.65% to $1.8 billion in 2024, then declined by 1.67% to $1.8 billion in 2025, then increased by 2.61% to $1.8 billion in 2026.
• Business Quant data shows BAX's Cost of Revenue at $1.8 billion in Q1 2026, $1.8 billion in Q1 2025, and $1.8 billion in Q4 2024.